{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:13:15Z","timestamp":1772842395502,"version":"3.50.1"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Asthma among adolescents (aged 12\u2013&lt;18 years) is a common condition with high disease burden. Many are undertreated, at risk of adverse outcomes and exhibit poor adherence to maintenance medication. As-needed albuterol\u2013budesonide 180\/160\u2009\u00b5g reduced the risk of severe exacerbations by 27% compared with as-needed albuterol 180\u2009\u00b5g in patients aged \u226512 years, with moderate-to-severe asthma receiving inhaled corticosteroid (ICS) maintenance therapy in the MANDALA trial. A small number of adolescents were included in MANDALA, but data were inconclusive. The randomised, double-blind, multicentre, phase IIIb ACADIA trial is evaluating as-needed albuterol\u2013budesonide versus as-needed albuterol in adolescents with asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A planned 440 adolescents (aged 12\u2013&lt;18 years) with asthma using as-needed albuterol with low- to high-dose ICS-containing maintenance medications (with or without other controllers) and who had \u22651 severe exacerbation in the previous 12 months are randomised to as-needed albuterol\u2013budesonide 180\/160\u2009\u00b5g or as-needed albuterol 180\u2009\u00b5g for 52 weeks while continuing their own maintenance therapy. The primary endpoint is the annualised rate of severe asthma exacerbations. Secondary endpoints are the time to first severe asthma exacerbation and annualised total systemic corticosteroid exposure for asthma per participant. To minimise the number of adolescents exposed to study medications, the treatment effect will be estimated by partially extrapolating results from the patient population in the MANDALA trial using a Bayesian dynamic borrowing approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the investigators\u2019 institutional review boards. Enrolment began in May 2024. Results will be presented at respiratory congresses and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06307665\">NCT06307665<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003843","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:13Z","timestamp":1772807713000},"page":"e003843","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of as-needed albuterol\u2013budesonide versus albuterol in patients with asthma aged 12 to &lt;18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct06307665","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03769090","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03847896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05505734","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06307665","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06307665","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Leonard Benjamin","family":"Bacharier","sequence":"first","affiliation":[{"name":"Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr. Children\u2019s Hospital, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengameh","family":"Raissy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pulmonary Division, University of New Mexico Health Sciences, Albuquerque, New Mexico, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bardsley","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Dunsire","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Hermansson","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raulin","family":"Surujbally","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olami","family":"Sobande","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Allergy, Asthma and Pediatric Pulmonology, Boys Town Hospital, Boys Town, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030606350548000_13.1.e003843.1","unstructured":"Centers for Disease Control and Prevention . Most recent asthma data. 2024. Available: https:\/\/www.cdc.gov\/asthma-data\/about\/most-recent-asthma-data.html [Accessed 18 Mar 2025]."},{"key":"2026030606350548000_13.1.e003843.2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JAA.S233268","article-title":"Treatment Adherence in Adolescents with Asthma","volume":"13","author":"Kaplan","year":"2020","journal-title":"J Asthma Allergy"},{"key":"2026030606350548000_13.1.e003843.3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss7004a1"},{"key":"2026030606350548000_13.1.e003843.4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1080\/02770903.2021.1955377","article-title":"Disease burden and treatment adherence among children and adolescent patients with asthma","volume":"59","author":"Averell","year":"2022","journal-title":"J Asthma"},{"key":"2026030606350548000_13.1.e003843.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00506-X"},{"key":"2026030606350548000_13.1.e003843.6","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. 2024. Available: https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf [Accessed 24 Jan 2025]."},{"key":"2026030606350548000_13.1.e003843.7","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1016\/j.jaip.2024.07.031","article-title":"Adherence Challenges and Strategies in Specific Groups With Asthma: Adolescents, Pregnancy, and Older Adults","volume":"12","author":"Anderson","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030606350548000_13.1.e003843.8","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A Practical Guide to Implementing SMART in Asthma Management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030606350548000_13.1.e003843.9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaip.2023.10.027","article-title":"Regulatory and Insurance Challenges Must Be Overcome in the United States to Meet Global Standards for Asthma Management","volume":"12","author":"Arora","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030606350548000_13.1.e003843.10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa2203163","article-title":"Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma","volume":"386","author":"Papi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026030606350548000_13.1.e003843.11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.chest.2023.03.035","article-title":"Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial","volume":"164","author":"Chipps","year":"2023","journal-title":"Chest"},{"key":"2026030606350548000_13.1.e003843.12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa2504544","article-title":"As-Needed Albuterol-Budesonide in Mild Asthma","volume":"393","author":"LaForce","year":"2025","journal-title":"N Engl J Med"},{"key":"2026030606350548000_13.1.e003843.13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/pst.2093","article-title":"Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing","volume":"20","author":"Best","year":"2021","journal-title":"Pharm Stat"},{"key":"2026030606350548000_13.1.e003843.14","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12242"},{"key":"2026030606350548000_13.1.e003843.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2026030606350548000_13.1.e003843.16","unstructured":"U.S. Food and Drug Administration . Ethical considerations for clinical investigations of medical products involving children: guidance for industry, sponsors, and irbs. 2022. Available: https:\/\/www.fda.gov\/media\/161740\/download [Accessed 04 Feb 2025]."},{"key":"2026030606350548000_13.1.e003843.17","unstructured":"U.S. Food and Drug Administration . E11A pediatric extrapolation. guidance for industry. 2024."},{"key":"2026030606350548000_13.1.e003843.18","unstructured":"European Medicines Agency . ICH guideline E11A on pediatric extrapolation. 2022."},{"key":"2026030606350548000_13.1.e003843.19","unstructured":"International Council for Harmonisation . ICH guideline E11A on pediatric extrapolation. 2022."},{"key":"2026030606350548000_13.1.e003843.20","unstructured":"AstraZeneca . AIRSUPRA (albuterol and budesonide) inhalation aerosol [package insert]. 2023."},{"key":"2026030606350548000_13.1.e003843.21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.anai.2025.07.008","article-title":"Albuterol\u2013budesonide rescue inhaler for asthma","volume":"136","author":"Chipps","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026030606350548000_13.1.e003843.22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40262-024-01422-y","article-title":"Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis","volume":"63","author":"Dimelow","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026030606350548000_13.1.e003843.23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s43441-024-00707-5","article-title":"Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial","volume":"59","author":"Sailer","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026030606350548000_13.1.e003843.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43441-023-00585-3","article-title":"Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study","volume":"58","author":"Edwards","year":"2024","journal-title":"Ther Innov Regul Sci"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:18Z","timestamp":1772807718000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjresp-2025-003843"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003843","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}